Significance of biochemical markers of myocardial injury in patients with acute myocardial infarction and COVID-19-Reference-Cited by-同舟云学术

Significance of biochemical markers of myocardial injury in patients with acute myocardial infarction and COVID-19

Published:2024-07-15 Issue:2 Volume:19 Page:69-77
ISSN:1992-6499
Container-title:Astrakhan medical journal
language:
Short-container-title:jour

Author:

Petrova O. V.¹,Tverdokhlebova D. K.¹,Shashin S. A.²,Zen’kov A. A.¹,Chernov I. I.¹

Affiliation:

1. Federal Center of Cardiovascular Surgery

2. Astrakhan State Medical University

Abstract

Clinical and instrumental data of patients with acute myocardial infarction are of little informative value for COVID-19 identification. The aim is to study the significance of myocardial injury markers on admission in patients with acute myocardial infarction on COVID-19 background. At admission to the hospital in 20 patients with acute myocardial infarction and COVID-19 in blood markers of myocardial damage (highly sensitive troponin T, myoglobin and creatine kinase MB fraction) were studied using immunochemiluminescent method on immunoenzyme analyzer “Cobas e 411” (“Roche Diagnostics”, Germany). The values of highly sensitive troponin T in patients with acute myocardial infarction and COVID-19 were significantly lower than in patients with acute myocardial infarction without COVID-19 (94.8 vs. 171.8 pg/ml). There were no statistically significant differences in the values of myoglobin and the MB creatine kinase fraction in the study groups. Thus, markers of myocardial damage in patients with acute myocardial infarction have no predictive value in relation to COVID-19.

Publisher

Astrakhan State Medical University

Reference24 articles.

1. Boytsov S. A. Influenza, novel coronavirus infection and cardiovascular disease. Kardiologicheskiy vestnik = Russian Cardiology Bulletin. 2021; 16 (1): 5–10. doi:10.17116/Cardiobulletin2021160115. (in Russ.).

2. Chilazi M., Duffy E. Y., Thakkar A. Michos E. D. COVID and Cardiovascular Disease: What We Know in 2021. Current Atherosclerosis Reports. 2021; 23 (7): 37. doi: 10.1007/s11883-021-00935-2.

3. Bansal M. Cardiovascular disease and COVID-19. Diabetes and Metabolic Syndrome. 2020; 14 (3): 247–250. doi: 10.1016/j.dsx.2020.03.013.

4. Chashchin M. G., Gorshkov A. Yu., Drapkina O. M. Features of the course of non ST elevation myocardial infarction in patients history COVID-19 in medium term. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2022; 25 (5–2): 16–17. (in Russ.).

5. Choudry F. A., Hamshere S. M., Rathod K. S., Akhtar M. M., Archbold R. A., Guttmann O. P., Woldman S., Jain A. K., Knight C. J., Baumbach A., Mathur A., Jones D. A. High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2020; 76 (10): 1168–1176. doi: 10.1016/j.jacc.2020.07.022.